Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 424-426

  Melnik, G ^a   Schwesinger, W H ^a   Teng, R ^b   Dogolo, L C ^b   Vincent, J ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031783519     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691576     Document Type: Article

References (15)

1. Hendershot EF: Fluoroquinolones. Infectious Disease Clinics of North America (1995) 9:715-730
2. Just PM: Overview of the fluoroquinolone antibiotics. Pharmacotherapy (1993) 13, Supplement 2:4-17
3. von Rosenstiel N, Adam D: Quinolone antibacterial: an update of their pharmacology and therapeutic use. Drugs (1994) 47:873-901
4. Hooper DC, Wolfson JS: Fluoroquinolone antimicrobial agents. New England Journal of Medicine (1991) 324:384-394
5. Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349-353
6. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy (1994) 38:2471-2476
7. Klugman K, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873-874
8. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE: Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy (1995) 36:385-394
9. Teng R, Tensfeldt TG, Liston TE, Foulds G: Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography. B. Biomedical Applications (1996) 675:53-59
10. Dalvie DK, Khosla N, Vincent J: Excretion and metabolism of trovafloxacin in humans. Drug Metabolism and Disposition (1997) 25:423-427
11. Wise R, Mortiboy D, Child J, Andrews JM: Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:47-49
12. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW: Determinants of non-compliance with short-term antibiotic regimens. British Medical Journal (1987) 295:814-818
13. Davey P, Parker S: Cost-effectiveness of once-daily oral antimicrobial therapy. Journal of Clinical Pharmacology (1992) 32:706-710
14. Teng R, Girard D, Gootz TD, Foulds G, Liston TE: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrobial Agents and Chemotherapy (1996) 40:561-566
15. Nicolle LE: Urinary tract infection in the elderly. Journal of Antimicrobial Chemotherapy (1994) 33, Supplement A: 99-109